British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update
- 22 September 2023
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 190 (2) , 270-272
Abstract
The article provides a pragmatic update of the British Association of Dermatologists guidelines for biologic therapy for psoriasis.Keywords
This publication has 6 references indexed in Scilit:
- Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisJAMA Dermatology, 2022
- A Framework for the Development of Living Practice Guidelines in Health CareAnnals of Internal Medicine, 2022
- Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysisBritish Journal of Dermatology, 2020
- British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid updateBritish Journal of Dermatology, 2020
- Living systematic reviews: 4. Living guideline recommendationsJournal of Clinical Epidemiology, 2017
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Journal of Investigative Dermatology, 2015